Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708845 · ClinicalTrials.gov registry record · Phase 1
US Zamto-cel Autoimmune Diseases
A Phase 1 study, sponsored by Miltenyi Biomedicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT06708845 is a Phase 1 study that is actively recruiting participants, run by Miltenyi Biomedicine. The registered enrollment target is 48 participants.
The verdict
NCT06708845, a Phase 1 study, is actively recruiting participants, sponsored by Miltenyi Biomedicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL zamtocabtagene autoleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06708845
The ClinicalTrials.gov registry entry for NCT06708845 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Miltenyi Biomedicine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06708845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06708845 about?
NCT06708845 is a clinical study titled "US Zamto-cel Autoimmune Diseases". AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.
What is the current status of trial NCT06708845?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-07. Estimated completion is 2028-07.
What interventions are being tested in trial NCT06708845?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), zamtocabtagene autoleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT06708845?
This trial is sponsored by Miltenyi Biomedicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.